Analysis Of Complication Treatment Design In Hepatitis B Patients In The Outpatient Facility Of Dr. Moewari Hospital, Surakarta

Afnisyah Nurcahyati; Kharisma Jayak Pratama; Niken Luthfiyanti

doi:10.55227/ijhet.v4i6.676

Authors

Afnisyah Nurcahyati Universitas Duta Bangsa
Kharisma Jayak Pratama Universitas Duta Bangsa
Niken Luthfiyanti Universitas Duta Bangsa

DOI:

https://doi.org/10.55227/ijhet.v4i6.676

Keywords:

Analys, Complication, Hepatitis B

Abstract

Hepatitis is an inflammation of the liver that is generally caused by a viral infection. There are five hepatitis viruses, namely Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis D Virus (HDV) and Hepatitis E Virus (HEV). Hepatitis B is a liver disease caused by the hepatitis B virus (HBV). HBV can cause acute or chronic liver inflammation, in a small number of cases it can progress to liver cirrhosis or liver cancer (Andriani et al., 2020). This study aims to determine the patient profile and use of hepatitis B drugs and evaluate Hepatitis B treatment in patients at the Outpatient Installation of Dr. Moewardi Regional Hospital using a non-experimental descriptive observational method with retrospective quantitative data collection. The results of the study showed that of the 99 hepatitis B patients, the majority were male (67.68%) and aged >55 years (46.5%). Most patients received antiviral therapy (60.61%), with tenofovir being the most commonly used drug (78.78%), followed by entecavir (17.17%). Evaluation of treatment suitability showed that all doses and frequencies of antiviral and hepatoprotective therapy administered were in accordance with national guidelines and MIMS references (100% compliance). Curcuma was the most frequently used hepatoprotective agent (64.64%). This indicates that the use of hepatitis B medications at Dr. Moewardi Regional Hospital is in accordance with applicable therapy standards. Based on a study of 99 hepatitis B patients, most patients received antiviral and supportive therapy according to guidelines. The use of medications, both antiviral and hepatoprotective, was appropriate in type, dose, and frequency. Patient management demonstrated rational and clinically appropriate therapy.

Downloads

Download data is not yet available.

References

Andriyani, A., dan Yusuf, Y. (2021). Evaluasi Rasionalitas Penggunaan Antivirus pada Pasien Hepatitis B Kronik Rawat Inap di RSUD Dr. Soetomo. Jurnal Farmasi Klinis Indonesia, 10(2), 99-106.

Andriyani, N., dan Yusuf, H. (2021). Evaluasi efektivitas terapi hepatitis B kronis di rumah sakit pemerintah. Jurnal Farmasi Klinik Indonesia, 10(2), 145–152.

Andriani, Y., Pradiftha Sari, C., Setyaningrum, N., dan Ndaru, C. (2020). Evaluasi Pengobatan Pada Pasien Hepatitis B Rawat Jalan Di Rumah Sakit Yogyakarta. Prosiding Seminar Nasional Hasil Penelitian dan Pengabdian Masyarakat, 1(1), 65–75.

Andriani, Y., Yulia, R., dan Hartinah, D. (2020). Evaluasi Pengobatan pada Pasien Hepatitis B Rawat Jalan di Rumah Sakit Yogyakarta. Prosiding Seminar Nasional Hasil Penelitian dan Pengabdian Masyarakat.

Badan Pusat Statistik. (2022). Statistik penduduk menurut kelompok umur. Badan Pusat Statistik Republik Indonesia.

Dewi, P. P., Widiana, I. G. R., dan Wiryanthini, A. A. D. (2024). Gangguan Fungsi Hati: Patogenesis dan Tatalaksana. Jurnal Penyakit Dalam.

Fitriani, K. E., dan Yulianti, T. (2022). Evaluasi Terapi Antiviral Pada Pasien Hepatitis B Kronis Di Instalasi Rawat Inap Rsud Dr. Moewardi Surakarta Periode Juni Tahun 2018-Juni Tahun 2019. Usadha Journal of Pharmacy, 1(1), 123–137.

Fitriani, R., dan Yulianti, D. (2022). Hubungan kepatuhan pasien terhadap keberhasilan terapi hepatitis B kronis. Jurnal Farmasi Sains dan Praktik, 9(1), 12–19.

Hidayat, A., Pratama, F., dan Wibisono, R. (2020). Efektivitas terapi analog nukleos(t)ida pada pasien hepatitis B kronis. Media Farmasi Indonesia, 17(3), 120–127.

Kementerian Kesehatan Republik Indonesia. (2011). Pedoman Penggunaan Obat Rasional (POR). Jakarta: Kementerian Kesehatan Republik Indonesia

Kementerian Kesehatan Republik Indonesia. (2019). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hepatitis B. Jakarta: Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan RI. (2022). Petunjuk Teknis Tatalaksana Klinis Hepatitis B dan C. Jakarta: Kementerian Kesehatan Republik Indonesia.

Lestari, G. D., dan Kafesa, A. (2024). Kajian Penanganan Hepatitis B Berdasarkan Perilaku dan Pemeriksaan Molekuler. Mahayati Health Student Journal (MAHESA), 4(2), 123-130.

Lestari, I., Diah, P., dan Hartono, M. (2023). Panduan klinis nasional penatalaksanaan hepatitis B kronis. Jurnal Farmasi dan Kesehatan Indonesia, 12(2), 102–110.

Lestari, R., Suwito, P., dan Sulaiman, A. (2023). Analog Nukleosida/Nukleotida sebagai Terapi Hepatitis B Kronis: Studi Kohort 3 Tahun. Jurnal Penyakit Dalam Indonesia, 10(1), 1-9.

Nugroho, A., dan Handayani, R. (2021). Faktor usia dan imunitas terhadap progresivitas hepatitis B kronik. Jurnal Penyakit Dalam Indonesia, 8(2), 85–92.

Pratama, H., dan Dewi, S. (2020). Edukasi gaya hidup sehat pada pasien hepatitis B kronis. Jurnal Promosi Kesehatan Indonesia, 18(3), 199–206.

PUSTAKA. Jurnal Kesehatan Tuanku Tambusai, 5(2), 52-60. (Kajian pustaka yang merangkum terapi HBV di Indonesia)

Sari, D. P., Rahmawati, I., dan Lestari, Y. (2019). Karakteristik pasien hepatitis B kronik berdasarkan usia dan faktor risiko di rumah sakit rujukan. Jurnal Kesehatan Masyarakat, 14(3), 210–218.

Triana, R., Putri, A. D., dan Yuliana, S. (2023). Gambaran karakteristik penderita hepatitis B berdasarkan jenis kelamin pada pendonor darah di Unit Transfusi Darah PMI Kota Bengkulu. Jurnal Kesehatan Masyarakat Indonesia, 18(1), 45–52.

Trisnaningtyas, R. W., Sari, C. P., dan Setyaningrum, N. (2017). Evaluasi Terapi pada Pasien Hepatitis B di RSUP Dr. Sardjito Yogyakarta. Jurnal Ilmiah Farmasi, 13(1), 27-33.

Ventiani, N., Rosita, Y., dan Lestari, R. (2012). Prevalensi HBsAg pada pendonor darah di Palang Merah Indonesia Cabang Padang. Jurnal Kesehatan Andalas, 1(2), 65–70.

World Health Organization (WHO). (2014). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization.

Wulandari, R., Nugroho, D., dan Putri, S. (2023). Profil pasien hepatitis B di RSUD tipe A: Analisis retrospektif. Jurnal Kedokteran Indonesia, 11(1), 22–29.